TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?

BACKGROUND: Cardiotoxicity in the form of cardiac arrhythmia, myocardial infarction, and angina-like symptoms are not rare complications of fluoropyrimidines as 5-Fluorouracil (5FU) and capecitabine. DISCUSSION: Tas-102, a novel oral fluoropyrimidine, was recently approved by FDA for the treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrelli, Fausto, Barni, Sandro, Bertocchi, Paola, Zaniboni, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932685/
https://www.ncbi.nlm.nih.gov/pubmed/27377645
http://dx.doi.org/10.1186/s12885-016-2409-8
_version_ 1782441107455475712
author Petrelli, Fausto
Barni, Sandro
Bertocchi, Paola
Zaniboni, Alberto
author_facet Petrelli, Fausto
Barni, Sandro
Bertocchi, Paola
Zaniboni, Alberto
author_sort Petrelli, Fausto
collection PubMed
description BACKGROUND: Cardiotoxicity in the form of cardiac arrhythmia, myocardial infarction, and angina-like symptoms are not rare complications of fluoropyrimidines as 5-Fluorouracil (5FU) and capecitabine. DISCUSSION: Tas-102, a novel oral fluoropyrimidine, was recently approved by FDA for the treatment of advanced and refractory colorectal cancer. Its unique mechanism of action doesn’t seem linked with cardiotoxicity in clinical trials reported so far. SUMMARY: TAS 102 may represent one of the drugs of choice for patients with advanced colorectal cancer with cardiac disease. This intriguing and clinically relevant issue is briefly examined.
format Online
Article
Text
id pubmed-4932685
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49326852016-07-06 TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape? Petrelli, Fausto Barni, Sandro Bertocchi, Paola Zaniboni, Alberto BMC Cancer Debate BACKGROUND: Cardiotoxicity in the form of cardiac arrhythmia, myocardial infarction, and angina-like symptoms are not rare complications of fluoropyrimidines as 5-Fluorouracil (5FU) and capecitabine. DISCUSSION: Tas-102, a novel oral fluoropyrimidine, was recently approved by FDA for the treatment of advanced and refractory colorectal cancer. Its unique mechanism of action doesn’t seem linked with cardiotoxicity in clinical trials reported so far. SUMMARY: TAS 102 may represent one of the drugs of choice for patients with advanced colorectal cancer with cardiac disease. This intriguing and clinically relevant issue is briefly examined. BioMed Central 2016-07-04 /pmc/articles/PMC4932685/ /pubmed/27377645 http://dx.doi.org/10.1186/s12885-016-2409-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Debate
Petrelli, Fausto
Barni, Sandro
Bertocchi, Paola
Zaniboni, Alberto
TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
title TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
title_full TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
title_fullStr TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
title_full_unstemmed TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
title_short TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
title_sort tas-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
topic Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932685/
https://www.ncbi.nlm.nih.gov/pubmed/27377645
http://dx.doi.org/10.1186/s12885-016-2409-8
work_keys_str_mv AT petrellifausto tas102thefirstcardiogentlefluoropyrimidineinthecolorectalcancerlandscape
AT barnisandro tas102thefirstcardiogentlefluoropyrimidineinthecolorectalcancerlandscape
AT bertocchipaola tas102thefirstcardiogentlefluoropyrimidineinthecolorectalcancerlandscape
AT zanibonialberto tas102thefirstcardiogentlefluoropyrimidineinthecolorectalcancerlandscape

Ejemplares similares